Therapeutic Coronary Angiogenesis

Advances in Organ Biology

Volumn 7, Issue C, 1999, Pages 215-279

  Flanagan, Michael ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0344912066     PISSN: 15692590     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1569-2590(08)60169-X     Document Type: Article

References (350)

1. Abdulali S.A., Baliga B.G., Clayden A.D., and Smith D.R. Coronary artery luminal diameter in aortic stenosis. Am. J. Cardiol. 55 (1985) 450-453
2. Adamis A.P., Shima D.T., Tolentino M.J., Gragoudas E.S., Ferrara N., Folkman J., D'Amore P.A., and Miller J.W. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch. Ophthalmol. 114 (1996) 66-71
3. Alberts G.F., Hsu D.K.W., Peifley K.A., and Winkles J.A. Differential regulation of acidic and basic fibroblast growth factor gene expression in fibroblast growth factor-treated rat aortic smooth muscle cells. Circ. Res. 75 (1994) 261-267
4. Allen K.B., Delrossi A.J., Realyvasquez F., Leftrak E.A., Shaar C.J., and Dowling R.D. Transmyocardial revascularization combined with coronary artery bypass grafting alone: Results of a prospective randomized, multicenter trial. Circulation. 98 (1998) 1-21
5. Amrani F.C., Cheaw S.L., Chevalier B., Paolaggi F., Jouquey S., Hamon G., and Swynghedauw B. Regression of left ventricular hypertrophy by converting enzyme inhibition in 12--15-month-old spontaneously hypertensive rats: Effects on coronary resistance and ventricular compliance in normoxia and anoxia. J. Cardiovasc. Pharmacol. 23 (1994) 155-165
6. Anderson P.G., Bishop S.P., and Digerness S.B. Vascular remodeling and improvement of coronary reserve after hydralazine treatment in spontaneously hypertensive rats. Circ. Res. 64 (1989) 1127-1136
7. Anversa P., Capasso J.M., Sonnenblick E.H., and Olivetti G. Mechanisms of myocyte and capillary growth in the infarcted heart. European Heart J. 11 B (1990) 123-132
8. Anversa P., and Sonnenblick E.H. Ischemic cardiomyopathy: Pathophysiologic mechanisms. Prog. Cardiovasc. Dis. 33 (1990) 49-70
9. Aoyagi T., Fujii A.M., Flanagan M.F., Currier J.J., Colan S.D., and Mirsky I. Myocardial function of immature and mature sheep with pressure overload hypertrophy. Am. J. Physiol. 262 (1992) H1036-H1048 (Heart Circ. Physiol. 32)
10. Arras M., Mollnau H., Strasser R., Wenz R., Ito W.D., Schaper J., and Schaper W. The delivery of angiogenic factors to the heart by microsphere therapy. Nature Biotech. 16 (1998) 159-162
11. Asahara T., Bauters C., Pastore C., Kearney M., Rossow S., Bunting S., Ferrara N., Symes J.F., and Isner J.M. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon injured rat carotid artery. Circulation 91 (1995) 2793-2801
12. Asahara T., Bauters C., Pastore C., Zheng L.P., Takeshita S., Bunting S., Ferrara N., Symes J.F., and Isner J.M. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 92 (1995) II365-II371 (Suppl. II)
13. Aviezer D., Hecht D., Safran M., Eisinger M., David G., and Yayon A. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell 79 (1994) 1005-1013
14. Bache R.J. Effects of hypertrophy on the coronary circulation. Prog. Cardiovasc. Dis. 31 (1988) 403-440
15. Baker K.M., Chernin M.I., Wixson S.K., and Aceto J.F. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am. J. Physiol. 259 (1990) H324-H332 (Heart Circ. Physiol. 28)
16. Banai S., Jaklitsch M.T., Casscells W., Shou M., Shrivastav S., Correa R., Epstein S.E., and Unger E.F. Effects of acidic fibroblast growth factor on normal and ischemic myocardium. Circ. Res. 69 (1991) 76-85
17. Banai S., Jaklitsch M.T., Shou M., Lazarous D.F., Scheinowitz M., Biro S., Epstein S.E., and Unger E.F. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 89 (1994) 2183-2189
18. Banai S., Pinson A., Chandra M., Lazarovici G., and Keshet E. Upregulation of vascular endothelial growth factor expression induced by myocardial ischemia: Implications for coronary angiogenesis. Cardiovas. Res. 28 (1994) 1176-1179
19. Barr E., Lin H., Bolling S.F., Engelman G.L., and Leiden J.M. Induction of angiogenesis following in vivo gene transfer into myocardium. Circulation 84 (1991) II-420 (Suppl. II)
20. Battler A., Scheinowitz M., Bor A., Hasdai D., Zvi V., Di Segni E., Varda-Bloom N., Nass D., Engelberg S., Eldar M., Belkin M., and Savion N. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. J. Am. Coll. Cardiol. 22 (1993) 2001-2006
21. 165 after intramuscular gene transfer promotes collateral vessel development. Circulation 97 (1998) 1114-1123
22. Bauters C., Asahara T., Zheng L.P., Takeshita S., Bunting S., Ferrara N., Symes J.F., and Isner J.M. Recovery of disturbed endothelium-dependent flow in the collateral-perfused rabbit ischemic hindlimb after administration of vascular endothelial growth factor. Circulation 91 (1995) 2802-2809
23. Bell L., and Madri J.A. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am. J. Pathol. 137 (1990) 7-12
24. Berk B.C., Alexander R.W., Brock T.A., Gimbrone Jr. M.A., and Webb R. Vasoconstriction: a new activity for platelet-derived growth factor. Science 232 (1986) 87-90
25. Bick R.L., and Ross E.S. Clinical use of intrapulmonary heparin. Semin. Thromb. Hemost. 11 (1985) 213-217
26. Blair S.N., Kampert J.B., Kohl H.W., Barlow C.E., Macera C.A., Paffenbarger R.S., and Gibbons L.W. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. JAMA. 276 (1996) 205-210
27. Blair S.N., Kohl H.W., Barlow C.E., Paffenbarger R.S., Gibbons L.W., and Macera C.A. Changes in physical fitness and all-cause mortality: A prospective study of healthy and unhealthy men. JAMA. 273 (1995) 1093-1098
28. Blair S.N., Kohl H.W., Paffenbarger R.S., Clark D.G., Cooper K.H., and Gibbons L.W. Physical fitness and all-cause mortality: A prospective study of healthy men and women. JAMA. 262 (1989) 2395-2401
29. Bombardini T., and Picano E. The coronary angiogenetic effect of heparin: Experimental basis and clinical evidence. Angiology 48 (1997) 969-976
30. Bonetti F., Margonato A., Mailhac A., Carandente O., Cappelletti A., Ballarotto C., and Chierchia S.L. Coronary collaterals reduce the duration of exercise-induced ischemia by allowing a faster recovery. Am. Heart J. 124 (1992) 48-55
31. Breisch E.A., White F.C., Hammond H.K., Flynn S., and Bloor C.M. Myocardial characteristics of thyroxine stimulated hypertrophy: A structural and functional study. Basic Res. Cardiol. 84 (1989) 345-358
32. Breisch E.A., White F.C., Nimmo L.E., and Bloor C.M. Cardiac vasculature and flow during pressure overload hypertrophy. Am. J. Physiol. 251 (1986) H1031-H1037 (Heart Circ. Physiol. 20)
33. Brilla C.G., Janicki J.S., and Weber K.T. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 83 (1991) 1771-1779
34. Brilla C.G., Janicki J.S., and Weber K.T. Impaired diastolic function and coronary reserve in genetic hypertension: Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ. Res. 69 (1991) 107-115
35. Buttrick P.M., Levite H.A., Schaible T.F., Ciambrone G., and Scheuer J. Early increases in coronary vascular reserve in exercised rats are independent of cardiac hypertrophy. J Appl. Physiol. 59 (1985) 1861-1865
36. Calderone A., Takashi N., Izzo N.J., Thaik C.M., and Colucci W.S. Pressure- and volume-induced left ventricular hypertrophies are associated with distinct myocyte phenotypes and differential induction of peptide growth factor mRNAs. Circulation 92 (1995) 2385-2390
37. Camenzind E., Kint P.-P., Di Mario C., Ligthart J., van der Giessen W., Boersma E., and Serruys P.W. Intracoronary heparin delivery in humans: Acute feasibility and long-term results. Circulation 92 (1995) 2463-2472
38. Canby C.A., and Tomanek R.J. Role of lowering arterial pressure on maximal coronary flow with and without regression of cardiac hypertrophy. Am. J. Physiol. 257 (1989) H1110-H1118 (Heart Circ. Physiol. 26)
39. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gersenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., Moons L., Collen D., Risau W., and Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380 (1996) 435-439
40. Carroll S.M., White F.C., Roth D.M., and Bloor C.M. Heparin accelerates coronary collateral development in a porcine model of coronary artery occlusion. Circulation 88 (1993) 198-207
41. Casscells W., Lappi D.A., Olwin B.B., Wai C., Siegman, Speir E.H., Sasse J., and Baird A. Elimination of smooth muscle cells in experimental restenosis: targeting of fibroblast growth factor receptors. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 7159-7163
42. Casscells W., Speir J., Sasse J., Klagsbrun M., Allen P., Lee M., Calvo, Chiba M., Haggroth L., Folkman J., and Epstein S.E. Isolation, characterization and localization of heparin binding growth factors in the heart. J. Clin. Invest. 85 (1990) 433-441
43. Chen C.-H., Nguyen H.H., Weilbaecher D., Luo S., Gotto A.M., and Henry P.D. Basic fibroblast growth factor reverses atherosclerotic impairment of human coronary angiogenesis-like responses in vitro. Atherosclerosis 116 (1995) 261-268
44. Cheng G.C., Libby P., Grodzinsky A.J., and Lee R.T. Induction of DNA synthesis by a single transient mechanical stimulus of human vascular smooth muscle cells: Role of fibroblast growth factor-2. Circulation 93 (1996) 99-105
45. Chilian W.M., Wangler R.D., Peters K.G., Tomanek R.J., and Marcus M.L. Thyroxine-induced left ventricular hypertrophy in the rat: Anatomical and physiological evidence for angiogenesis. Circ. Res. 57 (1985) 591-598
46. Chleboun J.O., Martins R.N., Mitchell C.A., and Chirila T.V. bFGF enhances the development of the collateral circulation after acute arterial occlusion. Biochem. Biophys. Res. Communic. 185 (1992) 510-516
47. Christian T.F., Gibbons R.J., Clements I.P., Berger P.B., Selvester R.H., and Wagner G.S. Estimates of myocardium at risk and collateral flow in acute myocardial infarction using electrocardiographic indexes with comparison to radionuclide and angiographic measures. J. Am. Coll. Cardiol. 26 (1995) 388-393
48. Cicutti N., Rakusan K., and Downey H.F. Coronary artery occlusion extends perfusion territory boundaries through microvascular collaterals. Basic Res. Cardiol. 89 (1994) 427-437
49. Clarke M.S.F., Caldwell R.W., Chiao H., Miyake K., and McNeil P.L. Contraction-induced cell wounding and release of fibroblast growth factor in heart. Circ. Res. 76 (1995) 927-934
50. Clowes A.W., and Karnovsky M.J. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 265 (1977) 625-626
51. Clozel J.P., Kuhn H., and Hefti F. Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension. J. Hypertens. 7 (1989) 267-275
52. Clozel J.P., Veniant M., Hess P., and Sprecher U. Effects of two angiotensin converting enzyme inhibitors and hydralazine on coronary circulation in hypertensive rats. Hypertension 18 (1991) 114-118 (Suppl. 4)
53. Cohen M., and Rentrop K.P. Limitation of myocardial ischemia by collateral circulation during sudden controlled coronary artery occlusion in human subjects: A prospective study. Circulation 74 (1986) 469-476
54. Cohen M.V. Exercise on coronary collaterals. (Letter) Am. Heart J. 125 (1993) 1807-1808
55. Cohen M.V., Chukwuogo N., and Yarlagadda A. Heparin does not stimulate coronary-collateral growth in a canine model of progressive coronary-artery narrowing and occlusion. Am. J. Med. Sci. 306 (1993) 75-81
56. Collins R., Peto R., Baigent C., and Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N. Engl. J. Med. 336 (1997) 847-860
57. Crisman R.P., Rittman B., and Tomanek R.J. Exercise-induced myocardial capillary growth in the spontaneously hypertensive rat. Microvascular Res. 30 (1985) 185-194
58. Cuevas P., Carceller F., Ortega S., Zago M., Nieto I., and Gimenez-Gallego G. Hypotensive activity of fibroblast growth factor. Science 254 (1991) 1208-1210
59. Cummins P., El Amrani A.-I.K., and El Amrani F. Fibroblast and transforming growth factors in the heart: A role in cardiac growth?. In: Cummins P. (Ed). Growth Factors and the Cardiovascular System (1995), Kluwer, Boston 17-30
60. Dameron K.M., Volpert O.V., Tarnsky M.A., and Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265 (1994) 1582-1584
61. Damon D.H., Lobb R.R., D'Amore P.A., and Wagner J.A. Heparin potentiates the action of acidic fibroblast growth factor by prolonging its biologic half-life. J. Cell Physiol. 138 (1989) 221-226
62. Davis S., Aldrich T.H., Jones P.F., Acheson A., Compton D.L., Jain V., Ryan T.E., Bruno J., Radziejewski C., Maisonpierre P.C., and Yancopoulos G.D. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87 (1996) 1161-1169
63. de Simone G., Devereux R.B., Koren M.J., Mensah G.A., Casale P.N., and Laragh J.H. Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. Circulation 93 (1996) 259-265
64. Devereux R.B. "Silent ischemia," ventricular arrhythmias, and complications of hypertension. Circulation 85 (1992) 1948-1950
65. Devereux R.B., de Simone G., Ganau A., Koren M.J., and Roman M.J. Left ventricular hypertrophy associated with hypertension and its relevance as a risk factor for complications. J. Cardivasc. Pharm 21 (1993) S38-S44 (Suppl. 2)
66. Devlin G.P., Yu E., Cusimano R.J., Wei K., Rakowski H., Richards J.A., Sole M.J., and Schwartz L. A single intracoronary bolus of basic fibroblast growth factor increases myocardial perfusion bed in a porcine model of chronic ischaemia. J. Am. Coll. Cardiol. 27 (1996) 102A
67. Dzau V.J., Gibbons G.H., Morishita R., and Pratt R.E. New perspectives in hypertension research. Potentials of vascular biology. Hypertension 23 (1994) 1132-1140
68. Edelman E.R., Adams D.H., and Karnovsky M.J. Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 3773-3777
69. Edelman E.R., and Karnovsky M.J. Vascular injury is mediated by a compound reversed by protamine sulfate. Circulation 86 (1992) I-H (Suppl. I)
70. Edelman E.R., and Karnovsky M.J. Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis. Circulation 89 (1994) 770-776
71. Edelman E.R., Mathiowitz E., Langer R., and Klagsbrun M. Controlled and modulated release of basic fibroblast growth factor. Biomaterials 12 (1991) 619-626
72. Edelman E.R., Nugent M.A., and Karnovsky M.J. Perivascular and intravenous administration of basic fibroblast growth factor: Vascular and solid organ distribution. Proc. Natl. Acad. Sci. U.S.A. 15 (1993) 1513-1517
73. Edelman E.R., Nugent M.A., Smith L.T., and Karnovsky M.J. Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries. J. Clin. Invest. 89 (1992) 465-473
74. Eisenlohr H., Schmiebusch H., and Strauer B.E. Regression of media hypertrophy in hypertensive coronary resistance vessels by antihypertensive therapy. Circulation 78 (1988) II-169 (Suppl. I)
75. Ejiri M., Fujita M., Miwa K., Hirai T., Yamanishi K., Sakai O., Ishizaka S., and Sasayama S. Effects of heparin treatment on collateral development and regional myocardial function in acute myocardial infarction. Am. Heart J. 119 (1990) 248-253
76. Ekelund L.-G., Haskell W.L., Johnson J.L., Whaley F.S., Criqui M.H., and Sheps D.S. Physical fitness as a predictor of cardiovascular mortality in asymptomatic North American men: The lipid research clinics mortality follow-up study. N. Engl. J. Med. 3319 (1988) 1379-1384
77. Engelberg H. Effects of heparin at the arterial wall. Heparin and the Prevention of Atherosclerosis (1990), Wiley-Liss, New York 73-103
78. Engelberg H., Kuhn R., and Steinman M. A controlled study of the effect of intermittent heparin therapy on the course of human coronary atherosclerosis. Circulation 13 (1956) 489-498
79. Engelmann G.L., Dionne C.A., and Jaye M.C. Acidic fibroblast growth factor and heart development: Role in myocyte proliferation and capillary angiogenesis. Circ. Res. 72 (1993) 7-19
80. Engler D.A. Use of vascular endothelial growth factor for therapeutic angiogenesis. (Editorial) Circulation 94 (1996) 1496-1498
81. Fager G., Camejo G., and Bondjers G. Heparin-like glycosaminoglycans influence growth and phenotype of human arterial smooth muscle cells in vitro, I: evidence for reversible binding and inactivation of the platelet-derived growth factor by heparin. In Vitro Cell Dev. Biol. 28A (1992) 168-175
82. Falkenham M., Gohlke P., Stoll M., and Unger T. The renin-angiotensin system in the heart and vascular wall: New therapeutic aspects. J. Cardiovasc. Pharm. 24 (1994) S6-S13 (Suppl. 2)
83. Fernandez L.A., Twickler J., and Mead A. Neovascularization produced by angiotensin II. J. Lab. Clin. Med. 105 (1985) 141-145
84. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J., and Moore M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380 (1996) 439-442
85. Fishbein M.C., and Siegel R.J. How big are coronary atherosclerotic plaques that rupture?. Circulation 94 (1996) 2662-2666
86. Flanagan, M.F., Aoyagi, T., Arnold, L., Currier, J., Bergau, D., Fujii, A. and Rakusan, K. (1999a). Coronary vascular changes and perfusion reserve in sheep with reversal of aortic stenosis. (Submitted).
87. Flanagan, M.F., Aoyagi, T., Arnold, L., Maute, C., Currier, J., Bergau, D., Warren, H. and Izumo, S. (1999b). Age, angiogenic growth factors and coronary adaptations to left ventricular pressure overload. (Submitted).
88. Flanagan, M.F., Aoyagi, T., Arnold, L., Maute, C., Fujii, A., Currier, J., Bergau, D., Warren, H. and Rakusan, K. (1999c). Effects of chronic heparin administration on coronary vascular adaptation to hypertension and ventricular hypertrophy. (In press).
89. Flanagan M.F., Aoyagi T., Currier J., Colan S.D., and Fujii A.M. Effect of young age on coronary adaptation to left ventricular pressure overload hypertrophy in sheep. J. Am. Coll. Cardiol. 24 (1994) 1786-1796
90. Flanagan M.F., Fujii A.M., Colan S.D., Flanagan R.G., and Lock J.E. Myocardial angiogenesis and coronary perfusion in left ventricular pressure overload hypertrophy in the young lamb: Inhibition with chronic protamine administration. Circ. Res. 68 (1991) 1458-1470
91. Flaumenhaft R., Moscatelli D., and Rifkin D.B. Heparin and heparan sulfate increase the radius of diffusion and action of basic fibroblast growth factor. J. Cell Biol. 111 (1990) 1651-1659
92. Flugelman M.Y., Virmani R., Correa R., Yu Z.-X., Farb A., Leon M.B., Elami A., Fu Y.-M., Casscells W., and Epstein S.E. Smooth muscle cell abundance and fibroblast growth factors in coronary lesions of patients with nonfatal unstable angina. A clue to the mechanisms of transformation from the stable to the unstable clinical state. Circulation 88 (1993) 2493-2500
93. Folkman J., and Klagsbrun M. Angiogenic factors. Science 235 (1987) 442-447
94. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. (Review). Nature Med. 1 (1995) 27-31
95. Franklin B.A. Exercise training and coronary collateral circulation. Med. Sci. Sports Exerc. 23 (1991) 648-653
96. Frielingsdorf J., Seiler C., Kaufman P., Vassalli G., Suter T., and Hess O.M. Normalization of abnormal coronary vasomotion by calcium antagonists in patients with hypertension. Circulation 93 (1996) 1380-1387
97. FRISC study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 347 (1996) 561-568
98. Fujii M., Nuno D.W., Lamping K.G., Dellsperger K.C., Eastham C.L., and Harrison D.G. Effect of hypertension and hypertrophy on coronary microvascular pressure. Circ. Res. 71 (1992) 120-126
99. Fujita M., Kiemoto M., Kishishita M., Otani H., Nohara R., Tanaka T., Tamaki S., Yamazato A., and Sasayama S. Elevated basic fibroblast growth factor in pericardial fluid of patients with unstable angina. Circulation 94 (1996) 610-613
100. Fujita M., Mikuniya A., Takahashi M., Gaddis R., Hartley J., McKown D., and Franklin D. Acceleration of coronary collateral development by heparin in conscious dogs. Jpn. Circ. J. 51 (1987) 395-402
101. Fujita M., Ohno A., Miwa K., Sasayama S., Futatsuya R., and Seto H. Long-term efficacy of heparin exercise by exercise TI-201 myocardial scintigraphy. Internal J. Cardiol. 40 (1993) 51-56
102. Fujita M., Sasayama S., Asnoi H., Nakajima H., Sakai O., and Ohno A. Improvement of treadmill capacity and collateral circulation as a result of exercise with heparin pretreatment in patients with effort angina. Circulation 77 (1988) 1022-1029
103. Fujita M., Sasayama S., Kato K., and Takaori S. Prospective, randomized, placebo-controlled, double-blind, multicenter study of exercise with enoxaprin pretreatment for stable angina. Am. Heart J. 129 (1995) 535-541 and Enoxaprin Study Group.
104. Fujita M., Yamanishi K., Hirai T., Ohno A., Miwa K., and Sasayama S. Comparative effect of heparin treatment with and without strenuous exercise on treadmill capacity in patients with stable effort angina. Am. Heart J. 122 (1991) 453-457
105. Fuster V., Badimon L., Badimon J.J., and Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes. (Review). New Engl. J. Med. 326 (1992) 242-250
106. Garg R., and Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE inhibitors trials. JAMA. 273 (1995) 1450-1456
107. Giordano F.J., Ping P., McKirnan M.D., Nozaki S., DeMaria A.N., Dillmann W.H., Mathieu-Costello O., and Hammond H.K. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat. Med. 2 (1996) 534-539
108. Gitay-Goren H., Soker S., Vlodovsky I., and Neufeld G. The binding of endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J. Biol. Chem. 267 (1992) 6093-6098
109. Given M.B., Lowe R.F., Gelvin C.R., Sander G.E., and Giles T.D. Preservation of left ventricular function and coronary flow by angiotensin I-converting enzyme inhibition in the hypertensive-diabetic Dahl rat. Am. J. Hypertens. 7 (1994) 919-925
110. Glagov S., Weisenberg E., Zarins C.K., Stankunavicius R., and Kolettis G.J. Compensatory enlargement of human atherosclerotic coronary arteries. N. Eng. J. Med. 316 (1987) 1371-1375
111. Gohlke P., Linz W., Scholkens B.A., Kuwer I., Bartenbach S., Schnell A., and Unger T. Angiotensin-converting enzyme inhibition improves cardiac function: role of bradykinin. Hypertension 23 (1994) 411-418
112. Gohlke P., Stoll P., Lamberty V., Mattfeld T., Mall G., van Even P., Martorana P., and Unger T. Cardiac and vascular effects of chronic angiotensin converting enzyme inhibition at subantihypertensive doses. J. Hypertens. 10 (1992) S141-S144
113. Goldman B.I., and Wurzel J. Effects of growth factors on human cardiac myocytes. In: Cummins P. (Ed). Growth Factors and the Cardiovascular System (1993), Kluwer, Boston 105-117
114. Gospodarowicz D., and Chen J. Heparin protects basic and acidic FGF from inactivation. J. Cell Physiol. 128 (1986) 475-478
115. Gotto F., Gotto K., Weindel K., and Folkman J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab. Invest. 69 (1993) 508-517
116. Gurfinkel E.P., Manos E.J., Mejail R.I., Cerda M.A., Duronto E.A., Gardia C.N., Daroca A.M., and Mautner B. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J. Am. Coll. Cardiol. 26 (1995) 313-318
117. Habib G.B., Heibig J., Forman S.A., Brown B.G., Roberts R., Terrin M.L., and Bolli R. Influence of coronary collateral vessels on myocardial infarct size in humans: Results of Phase I thrombolysis in myocardial infarction (TIMI) trial. Circulation 83 (1991) 739-746 the TIMI Investigators.
118. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
119. Harada K., Friedman M., Lopez J.J., Wang S.Y., Li J., Prasad P.V., Pearlman J.D., Edelman E.R., Sellke F.W., and Simons M. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J. Physiol. 270 (1996) H1791-H1802 (Heart Circ. Physiol. 39)
120. Harada K., Grossman W., Friedman M., Prasad P.V., Keighley C.S., Manning W.J., Selke F.W., and Simons M. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J. Clin. Invest. 94 (1994) 623-630
121. Hariawala M.D., Horowitz J.J., Esakof D., Sheriff D.D., Walter D.H., Keyt B., Isner J.M., and Symes J.F. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J. Surg. Res. 63 (1996) 77-82
122. Hariawala M.D., and Sellke F.W. Angiogenesis and the heart: Therapeutic implications. J. Royal Soc. Med. 90 (1997) 307-311
123. Harrison D.G., Marcus M.L., Dellsperger K.C., Lamping K.G., and Tomanek R.J. Pathophysiology of myocardial perfusion in hypertension. Circulation 83 (1991) III14-III18 (Suppl. III)
124. Hashimoto E., Ogita T., Nakaoka T., Matsuoka R., Takao A., and Kira Y. Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart. Am. J. Physiol. 267 (1994) H1948-H1954 (Heart Circ. Physiol. 36)
125. Hassoun P.M., Thompson B.T., and Hales C.A. Partial reversal of hypoxic pulmonary hypertension by heparin. Am. Rev. Respir. Dis. 145 (1992) 193-196
126. Henry T.D., Rocha-Singh K., Isner J.M., Kereiakes D.J., Giordano F.J., Simons M., Losordo D.W., Hendel R.C., Bonow R.O., Rothman J.M., Borbas E.R., and McCluskey E.R. Results of intracoronary recombinant human vascular endothelial growth factor (rhVEGF) administration trial. J. Am. Coll. Cardiol. 31 (1988) 65A
127. Henry T.D., Annex B.H., Azrin M.A., McKendall G.R., Willerson J.T., Hendel R.C., Giordano F.J., Klein R., Gibson C.M., Berman D.S., Luce C.A., and McCluskey E.R. Double-binded, placebo-controlled trial of recombinant human vascular endothelial growth factor---the VIVA trial. J. Am. Coll. Cardiol. 33 (1999) 384A
128. Hernandez I., Cowley A.W., Lombard J.H., and Greene A.S. Salt intake and angiotensin II alter microvessel density in the cremaster muscle of normal rats. Am. J. Physiol. 263 (1992) H664-H667 (Heart Circ. Physiol. 32)
129. Hirata Y., Eguchi S., and Tsujino M. Effects of manidipine on DNA and protein syntheses in cultured vascular smooth muscle and endothelial cells and on proto-oncogene expression. Blood Press Suppl. 3 (1992) 30-35
130. Hittinger L., Shannon R.P., Bishop S.P., Gelpi R.J., and Vatner S.F. Subendomyocardial exhaution of blood flow reserve and increased fibrosis in conscious dogs with heart failure. Circ. Res. 65 (1989) 971-980
131. Horrigan M.C.G., MacIsaac A.I., Nicolini F.A., Vince D.G., Lee P., Ellis S.G., and Topol E.J. Reduction in myocardial infarct size by basic fibroblast growth factor after temporary coronary occlusion in a canine model. Circulation 94 (1996) 1927-1933
132. Houck K.A., Leung D.W., Rowland A.M., Winer J., and Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267 (1992) 26031-26037
133. Htun P., Ito W., Kirsch K.-P., and Schaper W. aFGF induced cardioprotection in ischemic myocardium can be antagonized by suramin. Circulation 94 (1996) I-607
134. Hughes M.L., Mortensen F., and Shouri L. Comparison of continuous long-term heparin and oral anticoagulant therapy in patients with severe angina pectoris. Am. Heart J. 65 (1963) 615-627
135. Inoue M., Itoh H., Ueda M., Naruko T., Kojima A., Komatsu R., Doi K., Ogawa Y., Tamura N., Takaya K., Igaki T., Yamashita J., Chun T.-H., Masatsugu K., Becker A.E., and Nakao K. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions. Possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 98 (1998) 2108-2116
136. Iriarte M.M., Caso R., Murga N., Argumedo M.L., and Sagastagoitia D. Microvascular angina in systemic hypertension: Diagnosis and treatment with enalapril. Am. J. Cardiol. 76 (1995) 31D-34D
137. Isner J.M., Pieczek A., Schainfeld R., Blair R., Haley L., Asahara T., Rosenfield K., Razvi S., and Symes J.F. Arterial gene transfer of naked DNA in patients with critical limb ischemia. Circulation 94 (1996) I-591 (Suppl. I)
138. 165 in patient with ischaemic limb. Lancet 348 (1996) 370-374
139. Isner J.M., Walsh K., Symes J., Pieczek A., Takeshita S., Lowry J., Rossow S., Rosenfield K., Weir L., Brogi E., and Schainfeld R. Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. Circulation 91 (1995) 2687-2692
140. Isoyoma S. Hypertension and age-related changes in the heart. Implications for drug therapy. Drugs Aging 5 (1994) 102-115
141. Isoyama S., Ito N., Kuroha M., and Takishima T. Complete reversibility of physiological coronary vascular abnormalities in hypertrophied hearts produced by pressure overload in the rat. J. Clin. Invest. 84 (1989) 288-294
142. Ito N., Nitta Y., Ohtani H., Ooshima A., and Isoyama S. Remodeling of microvessels by coronary hypertension or cardiac hypertrophy in rats. J. Mol. Cell. Cardiol. 26 (1994) 49-59
143. Izumo S., Nadal-Ginard N., and Mahdavi V. Proto-oncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 339-343
144. Kan M., Wang F., Xu J., Crabb J.W., Hou J., and McKeehan W.L. An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science 259 (1993) 1918-1921
145. Kardami E., Liu L., Kishore S., Pasumarthi B., Doble B.W., and Cattini P.A. Regulation of basic fibroblast growth factor (bFGF) and FGF receptors in the heart. Ann. N.Y. Acad. Sci. 752 (1995) 353-369
146. Katz A.M. Cell death in the failing heart: Role of an unnatural growth response to overload. Clin. Cardiol. 18 (1995) IV36-IV44 (Suppl. IV)
147. Kaufmann P., Vassalli G., Lupi-Wagner S., Jenni R., and Hess O. Coronary artery dimensions in primary and secondary left ventricular hypertrophy. J. Am. Coll. Cardiol. 28 (1996) 745-750
148. Kaye D., Pimental D., Prasad S., Maki T., Berger H.-J., McNeil P.L., and Smith T.W. Role of transiently altered sarcolemmal membrane permeability and basic fibroblast growth factor release in the hypertrophic response of adult rat ventricular myocytes to increased mechanical activity in vitro. J. Clin. Invest. 97 (1996) 281-291
149. Kersten J.R., Pagel P.S., and Warltier D.C. Protamine inhibits coronary collateral development in a canine model of repetitive coronary occlusion. Am. J. Physiol. 268 (1995) H720-H728 (Heart Circ. Physiol. 37)
150. Klagsbrun M. The affinity of fibroblast growth factors (FGFs) for heparin; FGF-heparan sulfate interactions in cells and extracellular matrix. Curr. Opin. Cell Biol. 2 (1990) 857-863
151. Klein L.W., Agarwal J.B., Schneider R.M., Hermann G., Weintraub W.S., and Helfant R.H. Effects of previous myocardial infarction on measurements of reactive hyperemia and the coronary vascular reserve. J. Am. Coll. Cardiol. 8 (1986) 357-363
152. Kohama Y., Oka H., Murayama N., Iida K., Itoh M., Ying X., and Mimura T. Increase of migration of cultured endothelial cells by angiotensin-converting enzyme inhibitor derived from tuna muscle. J. Pharmacobio. Dyn. 15 (1992) 223-229
153. Krabatsch T., Tambeur L., Lieback E., Shaper F., and Hetzer R. Transmyocardial laser revascularization in the treatment of end-stage coronary artery disease. Ann. Thorac. Cardiovasc. Surg. 4 (1998) 64-71
154. Ku D.D., Zaleski J.K., Liu S., and Brock T.A. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am. J. Physiol. 265 (1993) H586-H592
155. Laham R.J., Hung D., and Simons M. Therapeutic myocardial angiogenesis using percutaneous intrapericardial drug delivery. Clin. Cardiol. 22 (1999) I6-I9 (Suppl. I)
156. Laham R.J., Sellke F.W., Ware J.A., Pearlman J.D., Edelman E.R., and Simons M. Results of a randomized, double-blind, placebo-controlled study of local perivascular basic fibroblast growth factor (bFGF) treatment in patients undergoing coronary artery bypass surgery. J. Am. Coll. Cardiol. 33 (1999) 383A
157. Laham R.J., Leimbach M., Chronos N.A., Vansant J.P., Pearlman J.D., Pewttigrew R., Guler H.-P., Whitehorse M.J., Hung D., Baim D.S., King III S.B., and Simons M. Intracoronary administration of recombinant fibroblast and growth factor-2 (FGF-2) in patients with severe coronary artery disease: Results of phase I. J. Am. Coll. Cardiol. 33 (1999) 383A
158. Laitinen M., Hartikainen J., Eranen J., Kiviniemi M., Hiltunen M.O., Laakso M., and Yla-Herttuala S. Catheter-mediated VEGF gene transfer to human coronary arteries after angioplasty. Safety results from phase 1 Kuopio angioplasty trial (KAT trial). Circulation. 98 (1998) I-322
159. LaMarre J., Wollenberg G.K., Gonias S.L., and Hayes M.A. Cytokine binding and clearance properties of proteinase-activated alpha 2-macroglobulins. Lab. Invest. 65 (1991) 3-14
160. Landau C., Jacobs A.K., and Haudenschild C.C. Intrapericardial basic fibroblast growth factor induces myocardial angiogenesis in a rabbit model of chronic ischemia. Am. Heart J. 129 (1995) 924-931
161. Laughlin M.H. Effects of exercise training on coronary circulation: Introduction. Med. Sci. Sports Exerc. 26 (1994) 1226-1229
162. Lazarous D.F., Scheinowitz M., Schou M., Hodge E., Rajanayagam M.A.S., Hunsberger S., Robison Jr. W.G., Stiber J.A., Correa R., Epstein S.E., and Unger E.F. Effects of chronic systemic administration of basic fibroblast growth factor on coronary collateral development in the canine heart. Circulation 91 (1995) 145-153
163. Lazarous D.F., Shou M., Scheinowitz M., Hodge E., Thirumurti V., Kitsiou A.N., Stiber J.A., Lobo A.D., Hunsberger S., Guetta E., Epstein S.E., and Unger E.F. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation 94 (1996) 1074-1082
164. Lee I.-M., Hsieh C.-C., and Paffenbarger Jr. R.S. Exercise intensity and longevity in men: The Harvard alumni health study. JAMA. 273 (1995) 1179-1184
165. Lee W.-S., Jain M.K., Arkonac B.M., Zhang D., Shaw S.-Y., Kashiki S., Maemura K., Lee S.-L., Hollenberg N.K., Lee M.-U., and Haber E. Thy-1, a novel marker for angiogenesis upregulated by inflammatory cytokines. Circ. Res. 82 (1998) 845-851
166. LeNoble F.A.C., Hekking J.W.M., Van Straaten H.W.M., Slaaf D.W., and Struyker-Boudier H.A.J. Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick membrane. Europ. J. Pharmacol. 195 (1991) 305-306
167. Levy D., Salomon M., D' Agostino R.B., Belanger M., and Kannel W.B. Prognostic implications of baseline electrocardiographic features and their serial change in subjects with electrocardiographic left ventricular hypertrophy. Circulation 90 (1994) 1786-1793
168. Levy D., Larson M.G., Vasan R.S., Kannel W.B., and Ho K.K.L. The progression from hypertension to congestive heart failure. JAMA. 275 (1996) 1557-1562
169. Li J., Brown L.F., Hibberd M.G., Grossman J.D., Morgan J.P., and Simons M. VEGF, fik-1, flt-1 expression in a rat myocardial infarction model of angiogenesis. Am. J. Physiol. 270 (1996) H1803-H1811
170. Light J.T., Bellan J.A., Roberts P., Force S.D., Chen I.-L., Kerstein M.D., Kadowitz P.J., and McNamara D.B. Heparin treatment enhances the recovery of neoendothelial acetylcholine-induced vascular relaxation after balloon catheter injury in the rabbit aorta. Circulation 88 (1993) 413-419
171. Linder V. Role of basic fibroblast growth factor and platlet-derived growth factor (B-chain) in neointima formation after arterial injury. Z. Kardiol. 84 (1995) 137-144 (Suppl. 4)
172. Lindner V., Majack R.A., and Reidy M.A. Basic fibroblast growth factor stimulates endothelial regrowth in denuded arteries. J. Clin. Invest. 85 (1990) 2004-2008
173. Linder V., Olson N.E., Clowes A.W., and Reidy M.A. Inhibition of smooth muscle cell proliferation in injured rat arteries. Interaction of heparin with basic fibroblast growth factor. J. Clin. Invest. 90 (1992) 2044-2049
174. Lissner L., Bengtsson C., Bjorkelund C., and Wedel H. Physical activity levels and changes in relation to longevity: a prospective study of Swedish women. Am. J. Epidemiol. 143 (1996) 54-62
175. Lopez J.J., Starebier A., Edelman E.R., Hibberd M.G., Caputo R.P., Carrozza J.P., Prasad P.V., Douglas P.S., Sellke F.W., and Simons M. Local bFGF treatment results in angiographic collateral development, dose related increase in coronary flow and myocardial function in chronic myocardial ischemia. Circulation 93 (1995) 1-67 (Suppl. I)
176. Lopez J.J., Edelman E.R., Stambler A., Thomas K.A., DiSalvo J., Hibberd M.G., Caputo R.P., Carrozza J.P., Douglas P.S., Sellke F.W., and Simons M. Perivascular delivery of prolonged half-life aFGF via EVAC results in angiographic collateral development, improvement in coronary flow and function in chronic myocardial ischemia. J. Am. Coll. Cardiol. 27 (1996) 30A (Suppl. A)
177. Lopez J.J., Edelman E.R., Stamler A., Hibberd M.G., Prasad P., Carrozza J.P., Douglas P.S., Sellke F.W., and Simons M. J. Pharm. Exp. Therap. 182 (1997) 385-390
178. Lopez J.J., Edelman E.R., Stamler A., Hibberd M.G., Prasad P., Thomas K.A., DiSalvo J., Caputo R.P., Carrozza J.P., Douglas P.S., Sellke F.W., and Simons M. Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia. Am. J. Physiol. 274 (1998) H930-H936
179. Luo Z., Diaco M., Murohara T., Ferrara N., Isner J.M., and Symes J.F. Vascular endothelial growth factor attenuates myocardial ischemia-reperfusion injury. Annals Thoracic Surg. 64 (1997) 993-998
180. Lyons-Giordano B., Brinker J.M., and Kefalides N.A. Heparin coordinately suppresses endothelial plasminogen activator inhibitor-1, fibrinectin and thrombospondin mRNA levels. In: Maragoudakis M.E., Gullino P., and Lelkes P.I. (Eds). Angiogenesis in Health and Disease (1992), Plenum, New York 127-133
181. Majak R.A., Goodman L.V., and Dixit V. Cell surface thrombospondin is functionally essential for vascular smooth muscle cell proliferation. J. Cell Biol. 106 (1988) 415-421
182. Mall G., Greber D., and Gharebhaghi H. Myokardprotektion and Hypertrophier-egression bei spontan hypertensiven Rratten durch Nifedipin and and Moxonidin---Stereologische Untersuchungen. Herz, Kreislauf. Regulation, Organprotektion und Organschaeden (1991), F.K. Schattauer-Verlag, Stuttgart 91-106
183. Mali M., Elenius K., Miettinen H.M., and Jalkanen M. Inhibition of basic fibroblast growth factor-induced growth promotion by overexpression of syndecan-1. J. Biol. Chem. 267 (1992) 17606-17610
184. Mannion J.D., Magno M.G., Spinale F.G., Bauer T.L., O'Brien Jr. J.E., and Morrison R.C. Basic fibroblast growth factor is associated with increased capillary density and preservation of muscle morphology in chronically stimulated, ischemic muscle. Circulation 94 (1996) 1-342 (Suppl. 1)
185. Marcus M.L., Harrison D.G., Chilian W.M., Koyanagi S., Inou T., Tomanek R.J., Martins J.B., Eastham C.L., and Hiratzka L.F. Alterations in the coronary circulation in hypertrophied ventricles. Circulation 75 (1987) 119-125 (Suppl. 1)
186. Mclnnes G.T. Hypertension and coronary artery disease: Cause and effect. J. Hypertens. 13 (1995) S49-56 (Suppl.)
187. McKirnan M.D., and Bloor C.M. Clinical significance of coronary vascular adaptations to exercise training. Med. Sci. Sports Exerc. 26 (1994) 1262-1268
188. Melandri G., Seprini F., Cervi V., Candiotti N., Palazzini E., Branzi A., and Magnani B. Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris: A randomized, placebo-controlled trial. Circulation 88 (1993) 2517-2523
189. Mesri E.A., Federoff H.J., and Brownlee M. Expression of vascular endothelial growth factor from a defective herpes simplex virus type 1 amplicon vector induces angiogenesis in mice. Circ. Res. 76 (1995) 161-167
190. Messerli F.H., and Aepfelbacher F.C. Hypertension and left-ventricular hypertrophy. Cardiol. Clin. 13 (1995) 549-557
191. Meurice T., Bauters C., Auffray J.L., Vallet, Hamon M., Valero F., Van Belle E., Lablanche J.-M., and Bertrand M.E. Basic fibroblast growth factor restores endothelium-dependent responses after balloon injury of rabbit arteries. Circulation 93 (1996) 18-22
192. Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R., Moller N.P.H., Risau W., and Ullrich A. High affinity VEGF binding and developmental expression suggest flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72 (1993) 835-846
193. Miyataka M., Ishikawa K., and Katori R. Basic fibroblast growth factor increased regional myocardial blood flow and limited infarct size of acutely infarcted myocardium in dogs. Angiology. 49 (1998) 381-390
194. Mizuno K., Horiuchi K., Matui H., Miyamoto A., Arakawa K., Shibuya T., Kurita A., and Nakamura H. Role of coronary collateral vessels during transient coronary occlusion during angioplasty assessed by hemodynamic, electrocardiographic and metabolic changes. J. Am. Coll. Cardiol. 12 (1988) 624-628
195. Moore R.L., and Korzick D.H. Cellular adaptations of the myocardium to chronic exercise. Prog. Cardiovasc. Dis. 37 (1995) 371-396
196. Motz W., and Strauer B.E. Left ventricular function and collagen content after regression of hypertensive hypertrophy. Hypertension 13 (1989) 43-50
197. Motz W., and Strauer B.E. Improvement of coronary flow reserve after long-term therapy with enalapril. Hypertension 27 (1996) 1031-1038
198. Motz W., Vogt M., Scheler S., Schwartzkopff B., and Strauer B.E. Verbesserung der Koronarreserve und Hypertrophieregression nach antihypertensiver Therapie mit einem Betarezeptorenblocker. Dtsch. Med. Wochenschr. 118 (1993) 535-540
199. Motz W.H., and Strauer B.E. Differential therapy of hypertensive heart disease. Am J. Cardiol. 65 (1990) 60G-64G
200. Mueller S.N., Thomas K.A., Di Salvo J., and Levine E.M. Stabilization by heparin of acidic fibroblast growth factor mitogenicity for human endothelial cells in vitro. J. Cell Physiol. 140 (1989) 439-448
201. 165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Circ. Res. 77 (1995) 1077-1086
202. Nabel E.G. Gene therapy for cardiovascular disease. Circulation 91 (1995) 541-548
203. Nabel E.G., Yang Z.Y., Plautz G., Forough R., Zhan X., Haudenschild C.C., Maciag T., and Nabel G.J. Recombinant fibroblast growth factor-1 promotes angiogenesis in arteries in vivo. Nature 362 (1993) 844-846
204. Niebauer J., Hambrecht R., Marburger C., Hauer K., Velich T., von Hodenberg E., Schlierf G., Kubler W., and Schuler G. Impact of intensive physical exercise and low-fat diet on collateral vessel formation in stable angina pectoris and angiographically confirmed coronary artery disease. Am. J. Cardiol. 76 (1995) 771-775
205. Nitenberg A., and Antony I. Epicardial coronary arteries are not adequately sized in hypertensive patients. J. Am. Coll. Cardiol. 27 (1996) 115-123
206. Norrby K., and Sorbo J. Heparin enhances angiogenesis by a systemic mode of action. Int. J. Exp. Path. 73 (1992) 147-155
207. Nuefeld G., and Gospodarowicz D. Protamine sulfate inhibits mitogenic activities of the extracellular matrix and fibroblast growth factor, but potentiates that of epidermal growth factor. J. Cell Physiol. 132 (1987) 287-294
208. Nugent M.A., Karnovsky M.J., and Edelman E.R. Vascular cell-derived heparan sulfate shows coupled inhibition of basic fibroblast growth factor and mitogenesis in vascular smooth muscle cells. Circ. Res. 73 (1993) 1051-1060
209. Oler A., Whooley M.A., Oler J., and Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: A meta-analysis. JAMA. 276 (1996) 811-815
210. Olivetti G., Cigola E., Lagrasta C., Ricci R., Quaini F., Monopoli A., and Ongi ni E. Spirapril prevents left ventricular hypertrophy, decreases myocardial damage and promotes angiogenesis in spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 21 (1993) 362-370
211. Olwin B.B., and Hauschka S.D. Fibroblast growth factor receptor levels decrease during chick embryogenesis. J. Cell Biol. 110 (1990) 503-509
212. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., and Folkman J. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
213. O'Reilly M.S., Holmgren L., Chen C., and Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2 (1996) 689-692
214. Ornitz D.M., Herr A.B., Nilsson M., Westman J., Svahn C.-M., and Waksman G. FGF binding and FGF receptor activation by synthetic heparan-derived di- and trisaccharides. Science 268 (1995) 432-436
215. Park J.E., Keller G.A., and Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix bound VEGF. Molec. Biol. Cell. 4 (1993) 1317-1326
216. Parker J.L., Oltman C.L., Muller J.M., Myers P.R., Adams H.R., and Laughlin M.H. Effects of exercise training on regulation of tone in coronary arteries and arterioles. Med. Sci. Sports Exerc. 26 (1994) 1252-1261
217. Parker T.G., Packer S.E., and Schneider M.D. Peptide growth factors can provoke "fetal" contractile protein gene expression in rat cardiac myocytes. J. Clin. Invest. 85 (1990) 507-514
218. Parker T.G., and Schneider M.D. Growth factors, proto-oncogenes, and plasticity of the cardiac phenotype. Annu. Rev. Physiol. 53 (1991) 179-200
219. Pasumarthi K.B.S., Kardami E., and Cattini P.A. High and low molecular weight fibroblast growth factor-2 increase proliferation of neonatal rat cardiac myocytes but have differential effects on binucleation and nuclear morphology: Evidence for both paracrine and intracrine actions of fibroblast growth factor-2. Circ. Res. 78 (1996) 126-136
220. Pearlman J.D., Hibberd M.G., Chuang M.L., Karada K., Lopez J.J., Gladstone S.R., Friedman M., Sellke F.W., and Simons M. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nat. Med. 1 (1995) 1085-1089
221. Pelletier M.P., Giaid A., Sivaraman S., Dorfman J., Li C.M., Philip A., and Chiu R.C. Angiogenesis and growth factor expression in a model of transmyocardial revascularization. Ann. Thorac. Surg. 66 (1998) 12-18
222. Pepine C.J. Angiotensin converting enzyme inhibitor and coronary artery disease. J. Hypertens. 12 (1994) S65-S71 (Suppl.)
223. Pepper M.S., Ferrara N., Orci L., and Montesano R. Potent synergysm between vascular endothelial growth factor and the basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem. Biophys. Res. Commun. 189 (1992) 824-831
224. Pfeffer M.A. Left ventricular remodeling after acute myocardial infarction. Annu. Rev. Med. 46 (1995) 455-466
225. Piatti P.M., Monti L.D., Valsecchi G., Conti M., Nasser R., Guazzini B., Fochesato E., Phan C.V., Pontiroli A.E., and Pozza G. Effects of low-dose heparin infusion on arterial endothelin-1 release in humans. Circulation 94 (1996) 2703-2707
226. Piek J.J., and Becker A.E. Collateral blood supply to the myocardium at risk in human myocardial infarction: A quantitative postmortem assessment. J. Am. Coll. Cardiol. 11 (1988) 1290-1296
227. Pijls N.H.J., Bech G.J.W., El Gamal M.I.H., Bonnier H.J.R.M., DeBruyne B., Van Gelder B., Michels H.R., and Koolen J.J. Quantification of recruitable coronary collateral blood flow in conscious humans and its potential to predict future ischemic events. J. Am. Coll. Cardiol. 25 (1995) 1522-1528
228. Pitscheider W., Erlicher A., Zammarchi A., Crepaz R., Romeo C., Oberhollenzer R., Mautone A., and Braito E. Left ventricular remodelling at 3 months from a first transmural infarct: The effect of physical activity and of the patency of the necrotic artery on changes in volume and segmental kinetics. G. Ital. Cardiol. 25 (1995) 421-431
229. Psaty B.M., Heckbert S.R., Koepsell T.D., Siscovick D.S., Raghunathan T.E., Weiss N.S., Rosendaal F.R., Lemaitre R.N., Smith N.L., Wahl P.W., Wagner E.H., and Furberg C.D. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 274 (1995) 620-625
230. Quyyumi A.A., Diodati J.G., Lakatos E., Bonow R.O., and Epstein S.E. Angiogenic effects of low molecular weight heparin in patients with stable coronary artery disease: A pilot study. J. Am. Coll. Cardiol. 22 (1993) 635-641
231. Rajanayagam S., Harrell R.L., Feldman S., Thirumurti V., Shou M., Doanes M., Lazarous D.F., Capogrossi M.C., Crystal R.G., Unger E.F., Epstein S.E., and Finkel T. Delivery of VEGF to ischemic tissue using adenoviral-modified autologous endothelial cells. Circulation 94 (1996) 1-646 (Suppl. 1)
232. Rakusan K. Cardiac growth, maturation, and aging. In: Zak R. (Ed). Growth of the Heart in Health and Disease (1984), Raven Press, New York 131-164
233. Rakusan K. Microcirculation in the stressed heart. In: Legato M.J. (Ed). The Stressed Heart (1987), Martinus Nijhoff, Dordrecht 107-123
234. Rakusan K., Cicutti N., Kazda S., and Turek Z. Effect of nifedipine on coronary capillary geometry in normotensive and hypertensive rats. Hypertension 24 (1994) 205-211
235. Rakusan K., Flanagan M.F., Geva T., Southern J., and Van Praagh R. Morphometry of human coronary capillaries during normal growth and the effect of age in left ventricular pressure-overload hypertrophy. Circulation 86 (1992) 38-46
236. Rakusan K., and Korecky B. Regression of cardiomegaly induced in newborn rats. Can. J. Cardiol. 1 (1985) 217-222
237. Rakusan K., and Turek Z. Protamine inhibits capillary formation in growing rat hearts. Circ. Res. 57 (1985) 393-398
238. Rakusan K., and Wicker P. Morphometry of the small arteries and arterioles in the rat heart: Effects of chronic hypertension and exercise. Cardiovasc Res. 24 (1990) 278-284
239. Rakusan K., Wicker P., Abdul-Samad M., Healy B., and Turek Z. Failure of swimming exercise to improve capillarization in cardiac hypertrophy of renal hypertensive rats. Circ. Res. 61 (1987) 641-647
240. Rivard A., Fabre J.-E., Silver M., Murohara T., Chen D., Asahara T., and Isner J.M. Age-dependent impairment of angiogenesis. Circulation 96 (1997) 1-18 (Suppl. I)
241. Robert J.T., and Wearn J.T. Quantitative changes in the capillary-muscle relationship in human hearts during normal growth and hypertrophy. Am Heart J. 21 (1941) 617-633
242. Roghani M., and Moscatelli D. Basic fibroblast growth factor is internalized through both receptor-mediated and heparan sulfate-mediated mechanisms. J. Biol. Chem. 267 (1992) 22156-22162
243. Rosendorff C. The renin-angiotensin system and vascular hypertrophy. J. Am. Coll. Cardiol. 28 (1996) 803-812
244. Rosengart T.K., Budenbender K.T., Duenas M., Mack C.A., Zhang Q.X., and Isom O.W. Therapeutic angiogenesis: A comparative study of the angiogenic potential of acidic fibroblast growth factor and heparin. J. Vasc. Surg. 26 (1997) 302-312
245. Rosengart T.K., Kuperschmid J.P., Maciag T., and Clark R.E. Pharmacokinetics and distribution of heparin-binding growth factor I (endothelial cell growth factor) in the rat. Circ. Res. 64 (1989) 227-234
246. Rosengart T.K., Patel S.R., Lee L.Y., Sanborn T.A., Hachamovitch R., Kligfield P.D., Hahn R.T., Isom O.W., and Crystal R.G. Safety of direct myocardial VEGF121 cDNA adenovirus-mediated angiogenesis gene therapy in conjunction with coronary bypass surgery. Circulation. 98 (1998) 1-325
247. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362 (1993) 801-809
248. 1 receptor subtype. Circ. Res. 73 (1993) 413-423
249. Sadoshima J., Xu Y., Slayter H.S., and Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75 (1993) 977-984
250. Safi Jr. J., Gloe T.R., DiPaula A.F., Becker L.C., and Capogrossi M.C. Adenovirus-mediated gene transfer of acidic fibroblast growth factor reduces the risk region in a rabbit model of myocardial infarction. Circulation 94 (1996) 1-590 (Suppl. 1)--1--591
251. Saksela O., Moscatelli D., Sommer A., and Rifkin D.B. Endothelial cell-derived heparan sulfate binds basic fibroblast growth factior and protects it from proteolytic degradation. J. Cell Biol. 107 (1988) 743-751
252. Sasayama S., and Fujita M. Recent insights into coronary collateral circulation. Circulation 85 (1992) 1197-1204
253. Schaper W. Collateral vessel growth in the human heart: Role of fibroblast growth factor-2. (Editorial) Circulation 94 (1996) 600-601
254. Schaper W., Gorge G., Winkler B., and Schaper J. The collateral circulation of the heart. Prog. Cardiovasc. Dis. 31 (1988) 57-77
255. Schaper W., and Ito W.D. Molecular mechanisms of coronary collateral vessel growth. Circ. Res. 79 (1996) 911-919
256. Scheuer J. Effects of physical training on myocardial vascularity and perfusion. Circulation 66 (1982) 491-495
257. Schieffer B., Wirger A., Meybrunn M., Seitz S., Holtz J., Riede U.N., and Drexler H. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 89 (1994) 2273-2282
258. Schlaudraff K., Schumacher B., von Specht B.U., Seitelberger R., Schlosser V., and Fasol R. Growth of "new" coronary vascular structures by angiogenic growth factors. Europ. J. Cardiothorac. Surg. 7 (1993) 637-644
259. Schmieder R.E., Martus P., and Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: A meta-analysis of randomized double-blind studies. JAMA. 275 (1996) 1507-1513
260. Schumacher B., Pecher P., von Specht B.U., and Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors. First clinical results of a new treatment of coronary heart disease. Circulation. 97 (1998) 645-650
261. Schunkert H., Dzau V.J., Tang S.S., Hirsch A.T., Apstein C.S., and Lorell B.H. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy: Effects on coronary resistance, contractility, and relaxation. J. Clin. Invest. 86 (1990) 1913-1920
262. Schunkert H., Jackson B., Tang S.S., Schoen F.J., Smits J.F.M., Apstein C.S., and Lorell B.H. Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. Circulation 87 (1993) 1328-1339
263. Schwartzkopff B., Motz W., Frenzel H., Vogt M., Knauer S., and Strauer B. Structural and functional alterations of the intramyocardial coronary arterioles in patients with hypertension. Circulation 88 (1993) 993-1003
264. Sellke F.W., Li J., Stamler A., Lopez J.J., Thomas K.A., and Simons M. Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia. Surgery 120 (1996) 182-188
265. Sellke F.W., Wang S.Y., Friedman M., Dai H.B., Harada K., Lopez J.J., and Simons M. Beta-adrenergic modulation of the collateral-dependent coronary microcirculation. J. Surg. Res. 59 (1995) 185-190
266. Sellke F.W., Wang S.Y., Friedman M., Harada K., Edelman E.R., Grossman W., and Simons M. Basic FGF enhances endothelium-dependent relaxation of the collateral-perfused porcine coronary microcirculation. Am. J. Physiol. 267 (1994) H1303-H1311 (Heart Circ. Physiol. 36)
267. Sellke F.W., Wang S.Y., Harada K., Lopez J.J., and Simons M. VEGF-induced angiogenesis as an alternate method of revascularization for chronic myocardial ischemia: Improved perfusion and vascular reactivity. J. Am. Coll. Cardiol. 27 (1996) 92A-93A (Suppl. A)
268. Sellke F.W., Wang S.Y., Stamler A., Lopez J.J., Li J.Y., and Simons M. Enhanced microvascular relaxations to VEGF and bFGF in chronically ischemic myocardium. Am. J. Physiol. 271 (1996) H713-H720
269. Sellke F.W., Laham R.J., Edelman E.R., Pearlman J.D., and Simons M. Therapeutic angiogenesis with basic fibroblast growth factor: Technique and early results. Annals Thoracic Surg. 65 (1998) 1540-1544
270. Sharma H.S., and Zimmerman R. Growth factors and development of coronary collaterals. In: Cummins P. (Ed). Growth Factors and the Cardiovascular System (1993), Kluwer, Boston 119-148
271. Shiota N., Miyazaki M., and Okunishi H. Increase of angiotensin converting enzyme gene expression in the hypertensive aorta. Hypertension 20 (1992) 168-174
272. Shipley R.A., Shipley L.J., and Wearn J.T. The capillary supply in normal and hypertrophied heart of rabbits. J. Exp. Med. 65 (1937) 29-41
273. Shyu K.-G., Lluo Y., Magner M., Tio R.A., Jiang C., Akita G.Y., Isner J.M., and Gregory R.J. Naked DNA encoding a Hypoxia-Inducible Factor la (HIF-1a)/VP16 hybrid transcription factor enhances angiogenesis in rabbit hindlimb ischemia: An alternative method for therapeutic angiogenesis utilizing a transcriptional regulatory system. Circulation. 98 (1998) 1-2
274. Skaletz-Rorowski A., Schmidt A., Breithardt G., and Buddecke E. Heparin-induced overexpression of basic fibroblast growth factor, basic fibroblast growth factor receptor, and cell-associated proteoheparan sulfate in coronary smooth muscle cells. Arterioscler Thromb. Vasc. Biol. 16 (1996) 1063-1069
275. Sladek T., Sladkova J., Kolar F., Papousek F., Cicutti N., Korecky B., and Rakusan K. The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats. Cardiovasc. Res. 31 (1996) 568-576
276. Slattery M.L., Jacobs Jr. D.R., and Nichaman M.Z. Leisure time physical activity and coronary heart disease death: The US railroad study. Circulation 79 (1989) 304-311
277. Soker S., Svahn C.M., and Neufeld G. Vascular endothelial growth factor is inactivated by binding to alpha 2-macroglobulin and the binding is inhibited by heparin. J. Biol. Chem. 268 (1993) 7685-7691
278. Sommer A., and Rifkin D.B. Interaction of heparin with human basic fibroblast growth factor: Protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan. J. Cell Physiol. 138 (1989) 215-220
279. Staab M.E., Simari R.D., Srivatsa S.S., Hasdai D., Pompili V.J., Holmes Jr. D.R., and Schwartz R.S. Enhanced angiogenesis and unfavorable remodeling in injured porcine coronary artery lesions: Effects of local basic fibroblast growth factor delivery. Angiology. 48 (1997) 753-760
280. Starvi G.T., Zachary I.C., Baskerville P.A., Martin J.F., and Erusalimsky J.D. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia. Circulation 92 (1995) 11-14
281. Stoll M., Steckelings M., Paul M., Bottari S.P., Metzger R., and Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J. Clin. Invest. 95 (1995) 651-657
282. Stone D.A., Corretti M.C., Hawke M.W., Herzog W., Rodriguez S., and Plotnick G.D. The influence of angiographically demonstrated coronary collaterals on the results of stress echocardiography. Clin. Cardiol. 18 (1995) 205-208
283. Strauer B.E., Vogt M., and Motz W. ACE-inhibitors and coronary microcirculation. Basic Res. Cardiol. 88 (1993) 97-106 (Suppl. 1)
284. Sundt T.M., and Rogers J.G. Transmyocardial laser revascularization for inoperable coronary artery disease. Curr. Opin. Cardiol. 12 (1997) 441-446
285. Suzuki J., Matsubara H., Urakami M., and Inada M. Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ. Res. 73 (1993) 439-447
286. Takeshita S., Pu L.-Q., Stein L.A., Sniderman A.D., Bunting S., Ferrara N., Isner J.M., and Symes J.F. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 90 (1994) II228-II234 (Suppl. II)
287. Takeshita S., Rossow S.T., Kearney M., Zheng L.P., Bauters C., Bunting S., Ferrar N., Symes J.F., and Isner J.M. Time course of increased cellular proliferation in collateral arteries after administration of vascular endothelial growth factor in a rabbit model of lower limb vascular insufficiency. Am. J. Pathol. 147 (1995) 1649-1660
288. Takahashi T., Schunkert H., Isoyama S., Wei J.Y., Nadal-Ginard B., Grossman W., and Izumo S. Age-related differences in the expression of proto-oncogene and contractile protein genes in response to pressure overload in the rat myocardium. J. Clin. Invest. 89 (1992) 939-946
289. Talafih K., Briden K.L., and Weiss H.R. Thyroxine induced hypertrophy of the rabbit heart: Effect on regional oxygen extraction, flow and oxygen consumption. Circ. Res. 52 (1983) 272-279
290. Tasgal J., and Vaughan W.E.M. The effect of prolonged propranolol administration on myocardial transmural capillary density in young rabbits. J. Physiol. 315 (1981) 353-367
291. Taylor S., and Folkman J. Protamine is an inhibitor of angiogenesis. Nature 297 (1982) 307-312
292. 165 with soluble and cell associated flk-1 receptors. J. Biol. Chem. 269 (1994) 12456-12461
293. Thomas L. The Lives of a Cell: Notes of a Biology Watcher (1974), Penquin Books, Viking Press, New York
294. Thompson R.W., Orlidge A., and D'Amore P.A. Heparin and growth control of vascular cells. Ann. N.Y. Acad. Sci. 556 (1989) 255-267
295. Tomanek R.J. Exercise-induced coronary angiogenesis: a review. Med. Sci. Sports Exerc. 26 1245--1251 (1994) H125-H131
296. Tomanek R.J., Aydelotte M.R., Anderson K.E., and Torry R.J. Coronary blood flow in senescent rats with late-onset hypertension. Am. J. Physiol. 264 (1993) H1854-H1860 (Heart Circ. Physiol. 33)
297. Tomanek R.J., Aydelotte M.R., and Butters C.A. Late-onset renal hypertension in old rats alters myocardial microvessels. Am. J. Physiol. 256 (1989) (Heart Circ. Physiol. 25)
298. Tomanek R.J., Connell P.M., Butters C.A., and Torry R.J. Compensated coronary microvascular growth in senescent rats with thyroxine-induced cardiac hypertrophy. Am. J. Physiol. 268 (1995) H419-H425 (Heart Circ. Physiol. 37)
299. Tomanek R.J., Palmer P.J., Peiffer G.L., Schreiber K.L., Eastham C.L., and Marcus M.L. Morphometry of canine arterioles, and capillaries during hypertension and left ventricular hypertrophy. Circ. Res. 58 (1986) 38-46
300. Tomanek R.J., and Torry R.J. Growth of the coronary vasculature in hypertrophy: Mechanisms and model dependence. Cell. Mol. Biol. Res. 40 (1994) 129-136
301. Tomanek R.J., Wangler R.D., and Bauer C.A. Prevention of coronary vasodilator reserve decrement in spontaneously hypertensive rats. Hypertension 7 (1985) 533-540
302. Tornig J., Amann K., Ritz E., Nichols C., Zeier M., and Mall G. Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the hearts of rats with renal failure: The effects of ramipril, nifedipine and moxonidine. J. Am. Soc. Nephrol. 7 (1996) 667-675
303. Tsurumi Y., Kearney M., Chen D., Silver M., Takeshita S., Yang J., Symes J.F., and Isner J.M. Treatment of acute limb ischemia by intramuscular injection of vascular endothelial growth factor gene. Circulation 96 (1997) II382-II388 (Suppl. II)
304. Turek Z., Kubat K., Kazda S., Hoofd L., and Rakusan K. Improved myocardial capillarisation in spontaneously hypertensive rats treated with nifedipine. Cardiovasc. Res. 21 (1987) 725-729
305. Turek Z., Kazda S., Elvers J.W.H., Hoofd L., Ringnalda B.E.M., and Rakusan K. Nisoldipine prevents rarefaction of myocardial capillarization in spontaneously hypertensive rats. In: Lichtlen P.R., and Krayenbuhl H.P. (Eds). New Aspects of Nisoldipine (1990), Schattauer, Stuttgart 41-49
306. Uchida Y., Yanagisawa-Miwa A., Nakamura F., Yamada K., Tomaru T., Kimura K., and Morita T. Angiogenic therapy of acute myocardial infarction by intrapericardial injection of basic fibroblast growth factor and heparin sulfate: an experimental study. Am. Heart J. 130 (1995) 1182-1188
307. Unger E.F., Banai S., Shou M., Jaklitsch M., Hodge E., Correa R., Jaye M., and Epstein S.E. A model to assess interventions to improve collateral blood flow: Continuous administration of agents into the left coronary artery in dogs. Cardiovasc. Res. 27 (1993) 785-791
308. Unger E.F., Banai S., Shou M., Lazarous D.F., Jaklitsch M.T., Scheinowitz M., Correa R., Klingbeil C., and Epstein S.E. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am. J. Physiol. 266 (1994) H1588-H1595 (Heart Circ. Physiol. 35)
309. Unger T., Mattfeldt T., Lamberty V., Bock P., Mall G., Linz W., Scholkens B.A., and Gohlke P. Effect of early onset angiotensin converting enzyme inhibition on myocardial capillaries. Hypertension 20 (1992) 478-482
310. Unger E.F., Sheffield C.D., and Epstein S.E. Heparin promotes the formation of extracardiac to coronary anastomoses in a canine model. Am. J. Physiol. 260 (1991) H1625-H1634 (Heart Circ. Physiol. 29)
311. Unger E.F., Shou M., Sheffield C.D., Hodge E., Jaye M., and Epstein S.E. Extracardiac to coronary anastomoses support regional left ventricular function in dogs. Am. J. Physiol. 264 (1993) H1567-H1574 (Heart Circ. Physiol. 33)
312. Uren N.G., Crake T., Lefroy D.C., deSilva R., Davies G.J., and Maseri A.
313. Vaisman N., Gospodarowicz D., and Neufeld G. Characterization of the receptors for vascular endothelial growth factor. J. Biol. Chem. 265 (1990) 19461-19466
314. Vale P.R., Rauh G.F., Wuensch D.I., Pieczek A.M., and Schainfeld R.M. Influence of vascular endothelial growth factor on diabetic retinopathy. Circulation. 98 (1998) 1-353
315. Vale P.R., Losordo D.W., Dunnington C.H., Lathi K., Esakof D.D., Symes J.F., and Isner J.M. Direct myocardial injection of VEGF for patients with chronic myocardial ischemia. J. Am. Coll. Cardiol. 33 (1999) 384A
316. Vanoverschelde J.-L.J., Wijns W., Depre C., Essamri B., Heyndrickx G.R., Borgers M., Bol A., and Melin J.A. Mechanisms of chronic regional postischemic dysfunction in humans: New insights from the study of noninfarcted collateral-dependent myocardium. Circulation 87 (1993) 1513-1523
317. Vatner S.F., and Hittinger L. Coronary vascular mechanisms involved in decompensation from hypertrophy to heart failure. J. Am. Coll. Cardiol. 22 (1993) 34A-40A Suppl. A
318. Vitullo J.C., Penn M.S., Rakusan K., and Wicker P. Effects of hypertension and aging on coronary arteriolar density. Hypertension 21 (1993) 406-414
319. Vogt M., and Strauer B.E. Response of hypertensive left ventricular hypertrophy and coronary microvascular disease to calcium antagonists. Am. J. Cardiol. 76 (1995) 24D-30D
320. Vogt M., and Strauer B.E. Systolic ventricular dysfunction and heart failure due to coronary microangiopathy in hypertensive heart disease. Am. J. Cardiol. 76 (1995) 48D-53D
321. Volpert O.V., Ward W.F., Lingen M.W., Chesler L., Solt D.B., Johnson M.D., Molteni A., Polverini P.J., and Bouck N.P. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J. Clin. Invest. 98 (1996) 671-679
322. Walgenbach K.J., Gratas C., Shestak K.C., and Becker D. Ischaemia-induced expression of bFGF in normal skeletal muscle: A potential paracrine mechanism for mediating angiogenesis in ischaemic skeletal muscle. Nature Med. 1 (1995) 453-459
323. Wang D.-H., and Prewitt R.L. Captopril reduces aortic and microvascular growth in hypertensive and normotensive rats. Hypertension 15 (1990) 68-77
324. Ware J.A., and Simons M. Angiogenesis in ischemic heart disease. Nature Med. 3 (1997) 158-164
325. Weber K.T., Sun Y., and Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 23 (1994) 869-877
326. Weich H.A., Iberg N., Klagsbrun M., and Folkman J. Transcriptional regulation of basic fibroblast growth factor gene expression in capillary endothelial cells. J. Cell Biochem. 47 (1991) 158-164
327. Weinberg E.O., Schoen F.J., George D., Kagaya Y., Douglas P.S., Litwin S.E., Schunkert H., Benedict C.R., and Lorell B.H. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation 90 (1994) 1410-1422
328. Weissberg P.L., Grainger D.J., Sanahan C.M., and Metcalfe J.C. Approaches to the development of selective inhibitors of vascular smooth muscle cell proliferation. Cardiovasc. Res. 27 (1993) 1191-1198
329. Whalen G.F., Shing Y., and Folkman J. The fate of intravenously administered bFGF and the effect of heparin. Growth Factors 1 (1989) 157-164
330. White F.C., and Bloor C.M. Coronary vascular remodeling and coronary resistance during chronic ischemia. Am. J. Cardiovasc. Pathol. 4 (1992) 193-202
331. White F.C., Bloor C.M., McKirnan M.D., and Carroll S.M. Exercise training in swine promotes growth of arteriolar bed and capillary angiogenesis in heart. J. Appl. Physiol. 85 (1998) 1160-1168
332. Whittaker P., Rakusan K., and Kloner R.A. Transmural channels can protect ischemic tissue. Assessment of longterm myocardial response to laser- and needle-made channels. Circulation. 93 (1996) 143-152
333. Wicker P., Tarazi R.C., and Kobayashi K. Coronary blood flow during the development and regression of left ventricular hypertrophy in renovascular hypertensive rats. Am. J. Cardiol. 51 (1983) 1744-1749
334. Willman V.L. Aortocoronary bypass with saphenous vein graft. (Commentary) JAMA. 276 (1996) 1521-1525
335. Wright A.J.A., and Hudlicka O. Capillary growth and changes in heart performance induced by chronic bradycardial pacing in the rabbit. Circ. Res. 49 (1981) 469-478
336. Wu H.M., Yuan Y., McCarthy M., and Granger H.J. Acidic and basic FGFs dilate arterioles of skeletal muscle through a NO-dependent mechanism. Am. J. Physiol. 271 (1996) H1087-H1093 (Heart Circ. Physiol. 40)
337. Wu J.-N., Edwards D., and Berecek K.H. Changes in renal angiotensin II receptors in spontaneously hypertensive rats by early treatment with the angiotensin-converting enzyme inhibitor captopril. Hypertension 23 (1994) 819-822
338. Yamamoto N., Kohmoto T., Anguo G., DeRosa C., Smith C.R., and Burkhoff D. Angiogenesis is enhanced in ischemic canine myocardium by transmural laser revascularization. J. Am. Coll. Cardiol. 31 (1998) 1426-1433
339. Yamamoto N., Kohmoto T., Anguo G., DeRosa C., Rabbani L.E., Smith C.R., and Burkhoff D. Basic fibroblast growth factor enhances the angiogenic effects of transmyocardial laser revascularization. Circulation. 98 (1998) 1-217
340. Yanagisawa-Miwa A., Uchida Y., Nakamura F., Tomaru T., Kido H., Kamijo T., Sugimoto T., Kaji K., Utsuyama M., Kurashima C., and Ito H. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 257 (1992) 1401-1403
341. Yang H.T., Deschenes M.R., Ogilvie R.W., and Terjung R.L. Basic fibroblast growth factor increases collateral blood flow in rats with femoral arterial ligation. Circ. Res. 79 (1996) 62-69
342. Yang H.T., Ogilvie R.W., and Terjung R.L. Heparin increases exercise-induced collateral blood flow in rats with femoral artery ligation. Circ. Res. 76 (1995) 448-456
343. Yayon A., Klagsbrun M., Esko J.D., Leder P., and Ornitz D.M. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64 (1991) 841-848
344. Ylitalo K., Jama L., Raatikainen P., and Peuhkurinen K. Adaptation to myocardial ischemia during repeated dynamic exercise in relation to findings at cardiac catheterization. Am. Heart J. 131 (1996) 689-697
345. Yokokawa K., Mandal A.K., Kohno M., Horio T., Murakawa K.-I., Yasunari K., and Takeda T. Heparin suppresses endothelin-1 action and production in spontaneously hypertensive rats. Am. J. Physiol. 263 (1992) R1035-R1041
346. Yokokawa K., Tahara H., Kohno M., Mandal A.K., Yanagisawa M., and Takeda T. Heparin regulates endothelin production through endothelium-derived nitric oxide in human endothelial cells. J. Clin. Invest. 92 (1993) 2080-2085
347. Yurenev A.P., Dyakonova H.G., Novikov I.D., Vitols A., Pahl L., Haynemann G., Wallrabe D., Tsifkova R., Romanovska L., Niderle P., Tsiskarishvili D.L., Davarashvili T., Gelovani K., Kochachidze T., and Balash A. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy: Multicenter trial. Am. J. Hypertens. 5 (1992) 1825-1895
348. Yusuf S. Calcium antagonists in coronary artery disease and hypertension: Time for reevaluation?. (Editorial) Circulation 92 (1995) 1079-1082
349. Zenker M.A., Kharma B.K., Quertermous T., Atkinson J.B., and Chapman G.D. Vascular endothelial growth factor promotes coronary collateral formation after myocardial infarction. J. Am. Coll. Cardiol. 25 (1995) 189A-190A (Suppl. A)
350. Ziche M., Morbidelli L., Masini E., Amerini S., Granger H.J., Maggi C.A., Geppetti P., and Ledda F. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J. Clin. Invest. 94 (1994) 2036-2044